Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IEC 2021 | Upcoming clinical trials for small molecules to treat autism spectrum disorder

James Clement • 20 Aug 2021
IEC 2021
General

James Clement, PhD, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India, talks on upcoming clinical trials in a compound that can restore the brain function to that of a healthy mouse when given after the brain is developed in autism spectrum disorder treatment. Dr Clement highlights the importance of this finding, as not many other compounds have restored brain function in a developed brain. This interview took place during the 34th International Epilepsy Congress, 2021.

More from James Clement

0:46
The next steps in autism treatment: gene therapy
James Clement • 20 Aug 2021
1:56
GABAergic signaling in autism spectrum disorders
James Clement • 20 Aug 2021
0:49
GABA suppressing drugs in epilepsy treatment
James Clement • 20 Aug 2021

Related Videos

2:51
RECOVER-NEURO: testing cognitive function interventions for long-COVID
Leigh Charvet • 23 Feb 2024
4:17
AI in neurology: considering the push and pull factors
Sanjay Budhdeo • 22 Mar 2024
2:59
New initiatives from NeuroNEXT: clinical trial support for academic and industry partners
Aleksandar Videnovic • 15 Apr 2024
1:17
Growing evidence for sleep and brain health
Karin Johnson • 14 Apr 2024
The content of VJNeurology is intended for healthcare professionals